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Purpose of the study
Promising research suggest that maraviroc (MVC) has favourable clinical outcome in HIV-infected patients (pts). Aim of the study
is to assess: durability, safety profile and immunovirological recovery in a large MVC-based cohort.
Methods
All HIV pts treated with antiretroviral therapy (ART) containing MVC for at least 6 months (all viruses CCR-5 tropic analyzed
by genotypic and phenotypic test) were recruited in an observational multicenter study. Eight Infectious Diseases Centers in
Liguria and Piedmont (Italy) collected at baseline and every 3 months demographics, clinical and immunovirological data on a
web-based system (by MedinfoDist, University of Genoa). We used SPSS for Pearson Chi square test and for generalized
estimating equation (GEE); in this model for longitudinal data and frequency analysis we considered altered: TCD45350/
mmc, HIVRNA 50 cp/ml, total cholesterol  200 mg/dl, triglycerides  160 mg/dl, transaminase 40 mg/dl, creatinine 1.3
mg/dl and we divided data in 5 time periods: baseline, 16, 912, 1524 and 2445 months.
Summary of results
We enrolled 55 pts: 36 (65%) males, median age 49.6 years (yrs) (range [r] 18.276.6, IQR 44.553.3), 11 (20%) HCVRNA-
positive, 4 (7%) HBsAg-positive, 1 both infection. Twenty-four (44%) pts were classified as CDC C stage, median nadir TCD4
was 219/mmc (r 11-529, IQR 125317), median duration of ART was 15.3 yrs (r 1.327.3, IQR 1216.8), median duration of
treatment with MVC was 23 months (r 647, IQR 1436). At baseline 42 (76%) pts had HIVRNA  50 cp/ml, 11 (20%)
HIVRNA550 cp/ml, 2 (4%) pts no data; on treatment at the last examination 53 pts (96%) had HIVRNA550 cp/ml, 2 pts still had
HIVRNA 50 cp/ml (CCR5 tropic) and median TCD4 count was 469/mmc (r 731802, IQR 302592). One pt died and only 2
pts shifted to X4. Chi square test at 912 months showed p0.0001 and the 80% of pts had TCD4 350/mmc; at the same
observation time 83.3% of pts had HIVRNA 550 cp/ml (p0.0001). About cholesterol, triglycerides, transaminase and
creatinine no significative differences were found and the median value showed no changes.
Conclusions
In our study a majority of pts treated with ARTcontaining MVC achieved a count of TCD4  350/mmc and HIVRNA undetectable
within 912 months. This regimen is a safe, feasible option and in pts with a poor immunological stage, MVC offered a
remarkable TCD4 count gain with limited X4 strains onset.
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